Cargando…

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer

LESSONS LEARNED. Vandetanib at a dose of 300 mg orally every day plus bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8, and 11 could be administered safely. Assessing outcomes in 17 patients with medullary thyroid cancer, investigators considered the combination to be more difficult to administe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Rivero, Jaydira, Edgerly, Maureen, Ward, Jean, Madan, Ravi A., Balasubramaniam, Sanjeeve, Fojo, Tito, Gramza, Ann W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2018
Materias:	Clinical Trial Results
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324636/ https://www.ncbi.nlm.nih.gov/pubmed/30297385 http://dx.doi.org/10.1634/theoncologist.2018-0452

Ejemplares similares

A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
por: Burotto, Mauricio, et al.
Publicado: (2017)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape
por: Fojo, Tito, et al.
Publicado: (2020)

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer()
por: Bostan, Ecem, et al.
Publicado: (2022)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)
por: Vera Aguilera, Jesus, et al.
Publicado: (2018)

A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer
por: Del Rivero, Jaydira, et al.
Publicado: (2020)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
por: Fallahi, Poupak, et al.
Publicado: (2019)

Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer
por: Pietri, Elisabetta, et al.
Publicado: (2018)

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Liaw, Bobby C, et al.
Publicado: (2022)

Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy
por: Lodish, Maya, et al.
Publicado: (2015)

A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy
por: Hirbe, Angela C., et al.
Publicado: (2018)

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
por: Kim, Miso, et al.
Publicado: (2018)

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019)

S‐1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
por: Chen, Ye, et al.
Publicado: (2019)

A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
por: Segar, Jennifer M., et al.
Publicado: (2019)

A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study
por: Riedel, Richard F., et al.
Publicado: (2020)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2016)

A Phase II Trial of Selinexor (KPT‐330) for Metastatic Triple‐Negative Breast Cancer
por: Shafique, Michael, et al.
Publicado: (2019)

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
por: Grierson, Patrick M, et al.
Publicado: (2022)

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
por: Halfdanarson, Thorvardur R., et al.
Publicado: (2019)

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
por: Piperno-Neumann, Sophie, et al.
Publicado: (2016)

Phase II Study of Panitumumab in RAS Wild‐Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
por: Gulhati, Pat, et al.
Publicado: (2017)

A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
por: Lolli, Cristian, et al.
Publicado: (2017)

Physical Activity Intervention in Patients with Metastatic Breast Cancer During Active Treatment: Quality of Life and Function
por: Shachar, Shlomit Strulov, et al.
Publicado: (2022)

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer
por: Agarwal, Neeraj, et al.
Publicado: (2016)

Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
por: Shah, Carl‐Henrik, et al.
Publicado: (2018)

Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer
por: Ueda, Hiroto, et al.
Publicado: (2018)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma
por: Zhang, Yang, et al.
Publicado: (2022)

Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
por: Grande, Enrique, et al.
Publicado: (2013)

Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results
por: Passardi, Alessandro, et al.
Publicado: (2017)

Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance)
por: Sideras, Kostandinos, et al.
Publicado: (2022)

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
por: William, William N., et al.
Publicado: (2018)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rlpngedo2e9i3h0n0e9g51819p